Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-117,600
Closed -$16.8M 4106
2021
Q4
$16.8M Buy
117,600
+92,000
+359% +$15.8M 0.01% 1177
2021
Q3
$5.31M Sell
25,600
-900
-3% -$198K ﹤0.01% 2011
2021
Q2
$5.63M Buy
26,500
+6,200
+31% +$1.14M ﹤0.01% 1986
2021
Q1
$3.68M Buy
+20,300
New +$4.05M ﹤0.01% 2330
2017
Q1
Sell
-5,810
Closed -$146K 3982
2016
Q4
$146K Buy
+5,810
New +$169K ﹤0.01% 3886

Other funds holding NVAX

Credit Suisse's NVAX Position: Q1 2024 in Review

Credit Suisse reduced its Novavax (NVAX) stake by 10% in Q1 2024, selling an estimated $218K and leaving 405,846 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Credit Suisse first reported a position in NVAX in Q2 2013 and has held it in 42 quarters since. The position peaked at $58.5M in Q3 2021. 202 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Credit Suisse held 405,846 shares of Novavax worth $1.94M as of Q1 2024.
  • Credit Suisse sold 46,931 Novavax shares in Q1 2024, an estimated $218K.
  • Novavax made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1871 holding.
  • Credit Suisse first reported a position in Novavax in Q2 2013 and has held it in 42 quarters since.
  • Credit Suisse's Novavax position peaked at $58.5M in Q3 2021.
  • 202 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.